within Pharmacolibrary.Drugs.ATC.C;

model C10AB11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.81,
    Cl             = 1.3333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 135 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.04,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 900
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AB11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Choline fenofibrate is an oral prodrug of fenofibric acid, a lipid-modifying agent in the fibrate class. It is used for the treatment of hypercholesterolemia, dyslipidemia, and hypertriglyceridemia, to reduce cholesterol and triglyceride levels in the blood. It is approved for use in several countries as an alternative to other fenofibrate formulations.</p><h4>Pharmacokinetics</h4><p>Estimate for healthy adults based on available literature interpolated for choline fenofibrate; fenofibrate PK considered as reference. No direct choline fenofibrate comprehensive PK model in peer-reviewed publications as of June 2024.</p><h4>References</h4><ol><li><p>Wei, X, et al., &amp; Liu, X (2017). Absolute oral bioavailability of fenofibric acid and choline fenofibrate in rats determined by ultra-performance liquid chromatography tandem mass spectrometry. <i>Biomedical chromatography : BMC</i> 31(4) –. DOI:<a href=&quot;https://doi.org/10.1002/bmc.3832&quot;>10.1002/bmc.3832</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27594083/&quot;>https://pubmed.ncbi.nlm.nih.gov/27594083</a></p></li><li><p>Kim, KS, et al., &amp; Choi, HG (2016). Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer. <i>Archives of pharmacal research</i> 39(4) 531–538. DOI:<a href=&quot;https://doi.org/10.1007/s12272-015-0701-9&quot;>10.1007/s12272-015-0701-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26992922/&quot;>https://pubmed.ncbi.nlm.nih.gov/26992922</a></p></li><li><p>Cao, Y, et al., &amp; Qi, R (2016). Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice. <i>Nanomedicine : nanotechnology, biology, and medicine</i> 12(8) 2449–2458. DOI:<a href=&quot;https://doi.org/10.1016/j.nano.2016.07.002&quot;>10.1016/j.nano.2016.07.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27438910/&quot;>https://pubmed.ncbi.nlm.nih.gov/27438910</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AB11;
